ライフサイエンスコーパス: right heart failure

1 e progression of tricuspid regurgitation and right heart failure.

2 riuretic peptide levels, and the presence of right heart failure.

3 terized by pulmonary vascular remodeling and right heart failure.

4 ients with severe pulmonary hypertension and right heart failure.

5 No deaths were associated with right heart failure.

6 TV) is increasing and results in intractable right heart failure.

7 te treatment strategies for PH and resultant right heart failure.

8 ypoxic pulmonary hypertension and ultimately right heart failure.

9 pulmonary arterial tree, eventually leads to right heart failure.

10 nt of pulmonary hypertension, and associated right heart failure.

11 in pulmonary vascular resistance leading to right heart failure.

12 -recognized but treatable etiology of severe right heart failure.

13 primary graft nonfunction or intraoperative right heart failure.

14 viduals present with dyspnoea or evidence of right heart failure.

15 years with death usually due to progressive right heart failure.

16 the case of a young man who developed acute right heart failure after combined heart and kidney tran

17 sidered when evaluating patients with severe right heart failure after PPM or ICD implantation.

18 Underlying causes of right heart failure and baseline hemodynamics did not pr

19 pulmonary hypertension is a risk factor for right heart failure and death after orthotopic heart tra

20 relentlessly progressive disease leading to right heart failure and death.

21 nt, the disorder progresses in most cases to right heart failure and death.

22 a progressive disease that ultimately causes right heart failure and death.

23 reased work of the right ventricle may cause right heart failure and liver congestion.

24 evealed a combination of left heart failure, right heart failure and moderate-to-severe tricuspid reg

25 c abnormalities that reflect the severity of right heart failure and predict adverse outcomes in pati

26 lung inflammation, vascular remodeling, and right heart failure and reverses hypoxic pulmonary hyper

27 y vascular resistance, eventually leading to right-heart failure and death.

28 Lower extremity edema, venous stenosis, right heart failure, and deep venous thrombosis occurred

29 th pulmonary hypertension, hypoxemia, and/or right heart failure, and may offer a new therapeutic app

30 The main causes of death included sepsis, right heart failure, and multiorgan failure.

31 nt with bisoprolol delays progression toward right heart failure, and partially preserves RV systolic

32 or adverse events included bleeding, stroke, right heart failure, and percutaneous lead infection.

33 nts included postoperative bleeding, stroke, right heart failure, and percutaneous lead infection.

34 Echocardiogram showed acute right heart failure, and pulmonary perfusion scan demons

35 ve clearer evidence now for predicting early right heart failure, and treating it in those patients w

36 antly left heart failure in combination with right heart failure, and tricuspid regurgitation; and (i

37 This leads to reduced cardiac output, right heart failure, and ultimately death.

38 t estimates for bleeding, stroke, infection, right heart failure, arrhythmias, and rehospitalizations

39 One patient died from right heart failure at 3 months.

40 26 critically ill adult patients with acute right heart failure defined by echocardiographic criteri

41 e pulmonary hypertension precipitating acute right heart failure, despite administration of milrinone

42 anifest pulmonary veno-occlusive disease and right heart failure, detectable at 8 months of age.

43 OF REVIEW: To review recent publications on right heart failure developing early and late after impl

44 early to remove fluid and reduce preload if right heart failure develops.

45 have provided good evidence about predicting right heart failure early after LVADs, though how to pre

46 Patients with right heart failure from cor pulmonale were classified a

47 n, retroperitoneal vascular constriction and right heart failure - has shown that serotonin and tachy

48 Patients with pulmonary hypertension and right heart failure have a high risk of clinical deterio

49 k of progressive tricuspid regurgitation and right heart failure in patients with moderate or lesser

50 Right heart failure is a cause of morbidity and mortalit

51 Right heart failure is an important cause of morbidity a

52 pertension, along with frequently associated right heart failure, is extremely challenging.

53 ure early after LVADs, though how to predict right heart failure late after LVAD is still unclear as

54 cyclin can be life-saving when perioperative right heart failure occurs due to exacerbation of pulmon

55 determined to be the direct cause of death (right heart failure or sudden death) in 37 (44%) patient

56 Bisoprolol delayed time to right heart failure (P<0.05).

57 ents with PAH and 75.7% of those who died of right heart failure received parenteral prostanoid thera

58 evices is associated with improved outcomes, right heart failure remains a considerable challenge.

59 Despite improved outcomes, right heart failure remains a significant challenge to s

60 ention that left heart failure has received, right heart failure remains understudied both at the pre

61 perience progressive symptoms of dyspnea and right heart failure resulting in significant morbidity a

62 amine reduces the incidence of postoperative right heart failure (RHF) in pediatric heart transplant

63 o associated with increased unadjusted early right heart failure (RHF).

64 Twelve patients died or developed right heart failure secondary to pulmonary hypertension

65 One of the deaths was from progressive right heart failure secondary to pulmonary hypertension

66 cured from explanted hearts of patients with right heart failure served as novel comparison samples.

67 1) How is right heart failure syndrome best defined?

68 th respect to medical therapies for treating right heart failure, there is evidence for the use of bo

69 ar and biventricular assist devices, such as right heart failure, valvular regurgitation, cardiac arr

70 s with dyspnea, exercise intolerance, and/or right heart failure who have elevated pulmonary artery s

71 ped for treating patients with severe TR and right heart failure with prohibitive surgical risk.

72 ications (one constrictive pericarditis, two right heart failures without underlying infection, and o